ChordNews
← All news

Genmab stock surges 16% on positive cancer trial results

By ChordNews · First written

Genmab stock surges 16% on positive cancer trial results
Image: investing.com
Comments 0

Summary

Investing.com reports that Genmab's stock surged 16% after positive results from a cancer trial. The article is known only from its headline, so it gives no further details on the trial or the company's outlook.

This continues an earlier story: Xencor stock surges on positive cancer drug trial data

Later: Genmab Stock Rallies on Stellar Cancer-Drug Data, Adding $10 Billion in a Week · Genmab's shares double in three months after a string of cancer drug trial wins

Timeline

  1. Investing.com

    Source ↗

    Reports that Genmab's stock surged 16% on positive cancer trial results.

Comments

No comments yet.

    to like and comment.

    © 2026 ChordNews